CD8A and hepatocellular carcinoma: As FOLR2+ oncofetal TAMs inhibit the response of CD8+ T cells in HCC [17], this observation of atezolizumab suggests it likely acts to reverse inhibition by TAMs and may be reflected following durvalumab, an anti-PD-L1.